Literature DB >> 16434545

Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice.

Ken-Ichi Nezasa1, Xianbin Tian, Maciej J Zamek-Gliszczynski, Nita J Patel, Thomas J Raub, Kim L R Brouwer.   

Abstract

This study characterized the hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein (CDF), a model Abcc2/Mrp2 (canalicular) and Abcc3/Mrp3 (basolateral) substrate, in perfused livers from male C57BL/6 wild-type, Abcg2-/-, and Abcc2-/- mice. After single-pass liver perfusion with 1 muM CDF diacetate for 30 min and an additional 30-min perfusion with CDF-free buffer, cumulative biliary excretion of CDF in Abcg2-/- mice was significantly higher than in wild-type mice (65 +/- 6 and 47 +/- 15% of dose, respectively, p < 0.05), whereas CDF recovery in bile of Abcc2-/- mice was negligible. Cumulative recovery of CDF in perfusate was significantly higher in Abcc2-/- (90 +/- 8% of dose) relative to wild-type (35 +/- 11% of dose) mice. Compartmental pharmacokinetic analysis revealed that the rate constant for CDF biliary excretion was significantly increased in Abcg2-/- (0.061 +/- 0.005 min(-1)) compared with wild-type (0.039 +/- 0.011 min(-1)) mice. The rate constant governing the basolateral excretion of CDF was approximately 4-fold higher in Abcc2-/- (0.12 +/- 0.02 min(-1)) relative to wild-type (0.030 +/- 0.011 min(-1)) mice but was not altered in Abcg2-/- (0.031 +/- 0.004 min(-1)) mice. Hepatic Abcc3 protein levels, determined by immunoblot analysis, were approximately 60% higher in Abcc2-/- mice than in wild-type mice. In contrast, neither Abcc3 protein levels nor Abcc2 mRNA levels were altered in Abcg2-/- relative to wild-type mice. These data in knockout mouse models demonstrate that loss of expression and function of one canalicular transport protein may change the route and/or extent of excretion into bile or perfusate because of alterations in the function of other basolateral or canalicular transport proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434545     DOI: 10.1124/dmd.105.007922

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

1.  Relationship between drug/metabolite exposure and impairment of excretory transport function.

Authors:  Maciej J Zamek-Gliszczynski; J Cory Kalvass; Gary M Pollack; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-11-20       Impact factor: 3.922

2.  Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.

Authors:  John K Fallon; Philip C Smith; Cindy Q Xia; Mi-Sook Kim
Journal:  Pharm Res       Date:  2016-06-29       Impact factor: 4.200

Review 3.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

Authors:  Brandon Swift; Nathan D Pfeifer; Kim L R Brouwer
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

4.  Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Regulate the Disposition of Acacetin Glucuronides.

Authors:  Huangyu Jiang; Jia Yu; Haihui Zheng; Jiamei Chen; Jinjun Wu; Xiaoxiao Qi; Ying Wang; Xinchun Wang; Ming Hu; Lijun Zhu; Zhongqiu Liu
Journal:  Pharm Res       Date:  2017-04-18       Impact factor: 4.200

5.  Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.

Authors:  Zhen Yang; Wei Zhu; Song Gao; Taijun Yin; Wen Jiang; Ming Hu
Journal:  Drug Metab Dispos       Date:  2012-06-26       Impact factor: 3.922

6.  Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease.

Authors:  Jacqueline Bezençon; James J Beaudoin; Katsuaki Ito; Dong Fu; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-06-03       Impact factor: 3.922

Review 7.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

8.  Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.

Authors:  Xianbin Tian; Jun Li; Maciej J Zamek-Gliszczynski; Arlene S Bridges; Peijin Zhang; Nita J Patel; Thomas J Raub; Gary M Pollack; Kim L R Brouwer
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers.

Authors:  Xianbin Tian; Brandon Swift; Maciej J Zamek-Gliszczynski; Martin G Belinsky; Gary D Kruh; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-02-14       Impact factor: 3.922

10.  Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice.

Authors:  Xianbin Tian; Maciej J Zamek-Gliszczynski; Jun Li; Arlene S Bridges; Ken-ichi Nezasa; Nita J Patel; Thomas J Raub; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2007-10-03       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.